Concepts (107)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Myeloid, Acute | 9 | 2020 | 215 | 1.130 |
Why?
|
| Anthracyclines | 4 | 2018 | 62 | 0.410 |
Why?
|
| Bone Marrow | 2 | 2018 | 77 | 0.390 |
Why?
|
| Lysophospholipase | 1 | 2012 | 5 | 0.380 |
Why?
|
| Glycoproteins | 1 | 2012 | 44 | 0.370 |
Why?
|
| Heart Ventricles | 3 | 2018 | 155 | 0.350 |
Why?
|
| Geriatric Assessment | 4 | 2020 | 369 | 0.320 |
Why?
|
| Stroke Volume | 4 | 2018 | 440 | 0.310 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2018 | 491 | 0.270 |
Why?
|
| Ventricular Dysfunction, Left | 3 | 2018 | 184 | 0.250 |
Why?
|
| Antibiotics, Antineoplastic | 3 | 2018 | 75 | 0.230 |
Why?
|
| Ventricular Function, Left | 3 | 2017 | 287 | 0.230 |
Why?
|
| Hematologic Neoplasms | 2 | 2014 | 40 | 0.210 |
Why?
|
| Aged | 13 | 2020 | 11022 | 0.170 |
Why?
|
| Antineoplastic Agents | 2 | 2017 | 628 | 0.170 |
Why?
|
| Female | 15 | 2020 | 21532 | 0.140 |
Why?
|
| Sulfides | 2 | 2018 | 27 | 0.140 |
Why?
|
| Caprylates | 2 | 2018 | 27 | 0.140 |
Why?
|
| Middle Aged | 13 | 2020 | 12726 | 0.140 |
Why?
|
| Resuscitation Orders | 1 | 2017 | 13 | 0.130 |
Why?
|
| Prospective Studies | 7 | 2020 | 2463 | 0.130 |
Why?
|
| Salvage Therapy | 2 | 2015 | 138 | 0.130 |
Why?
|
| Breast Neoplasms | 2 | 2014 | 806 | 0.130 |
Why?
|
| Cardiac Volume | 1 | 2017 | 13 | 0.130 |
Why?
|
| Intensive Care Units | 1 | 2017 | 123 | 0.120 |
Why?
|
| Leukemia | 2 | 2014 | 44 | 0.120 |
Why?
|
| Biopsy | 2 | 2018 | 273 | 0.120 |
Why?
|
| Depression | 2 | 2016 | 458 | 0.120 |
Why?
|
| Activities of Daily Living | 1 | 2016 | 267 | 0.110 |
Why?
|
| Cognition | 2 | 2016 | 576 | 0.110 |
Why?
|
| Male | 13 | 2020 | 20740 | 0.110 |
Why?
|
| Tubulin Modulators | 1 | 2014 | 10 | 0.110 |
Why?
|
| Humans | 15 | 2020 | 34562 | 0.110 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2015 | 118 | 0.110 |
Why?
|
| Aged, 80 and over | 6 | 2020 | 4157 | 0.100 |
Why?
|
| Azacitidine | 1 | 2013 | 29 | 0.100 |
Why?
|
| Lymphoma | 1 | 2013 | 40 | 0.100 |
Why?
|
| Antibodies, Monoclonal | 1 | 2014 | 271 | 0.090 |
Why?
|
| Crystallization | 1 | 2012 | 18 | 0.090 |
Why?
|
| DNA Methylation | 1 | 2013 | 147 | 0.090 |
Why?
|
| Adult | 8 | 2018 | 10030 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2014 | 1393 | 0.090 |
Why?
|
| Heart Failure | 1 | 2018 | 780 | 0.090 |
Why?
|
| Neoplasms | 1 | 2017 | 793 | 0.080 |
Why?
|
| Aorta | 1 | 2009 | 139 | 0.070 |
Why?
|
| Hospitalization | 1 | 2011 | 500 | 0.070 |
Why?
|
| Treatment Outcome | 4 | 2018 | 3623 | 0.070 |
Why?
|
| Predictive Value of Tests | 3 | 2014 | 939 | 0.060 |
Why?
|
| Mitoxantrone | 2 | 2018 | 20 | 0.060 |
Why?
|
| Comorbidity | 3 | 2013 | 596 | 0.060 |
Why?
|
| Cytarabine | 2 | 2018 | 59 | 0.060 |
Why?
|
| Recurrence | 2 | 2018 | 296 | 0.060 |
Why?
|
| Time Factors | 3 | 2017 | 2353 | 0.060 |
Why?
|
| Survival Rate | 2 | 2020 | 928 | 0.060 |
Why?
|
| Cardiovascular Diseases | 1 | 2013 | 1209 | 0.060 |
Why?
|
| Neoplasm Staging | 2 | 2018 | 486 | 0.050 |
Why?
|
| Remission Induction | 2 | 2015 | 97 | 0.050 |
Why?
|
| Mitochondria | 2 | 2018 | 219 | 0.050 |
Why?
|
| Drug Administration Schedule | 2 | 2015 | 306 | 0.050 |
Why?
|
| Young Adult | 3 | 2018 | 2831 | 0.050 |
Why?
|
| Retrospective Studies | 3 | 2017 | 3825 | 0.050 |
Why?
|
| Disease-Free Survival | 1 | 2020 | 354 | 0.040 |
Why?
|
| Cell Respiration | 1 | 2018 | 22 | 0.030 |
Why?
|
| Retreatment | 1 | 2018 | 43 | 0.030 |
Why?
|
| Patient Transfer | 1 | 2017 | 43 | 0.030 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2018 | 114 | 0.030 |
Why?
|
| Oxygen Consumption | 1 | 2018 | 167 | 0.030 |
Why?
|
| Cell Line | 1 | 2018 | 476 | 0.030 |
Why?
|
| Diastole | 1 | 2017 | 100 | 0.030 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2017 | 109 | 0.030 |
Why?
|
| Physical Examination | 1 | 2016 | 94 | 0.030 |
Why?
|
| Mental Health | 1 | 2016 | 126 | 0.030 |
Why?
|
| Asparaginase | 1 | 2015 | 5 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2016 | 214 | 0.030 |
Why?
|
| Risk Factors | 2 | 2013 | 4137 | 0.030 |
Why?
|
| Survivors | 1 | 2016 | 177 | 0.030 |
Why?
|
| Transplantation, Homologous | 1 | 2015 | 165 | 0.030 |
Why?
|
| Mobility Limitation | 1 | 2016 | 222 | 0.030 |
Why?
|
| Edema, Cardiac | 1 | 2014 | 14 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2015 | 510 | 0.030 |
Why?
|
| Drug Evaluation | 1 | 2013 | 15 | 0.030 |
Why?
|
| DNA, Neoplasm | 1 | 2013 | 55 | 0.030 |
Why?
|
| Positron-Emission Tomography | 1 | 2014 | 177 | 0.020 |
Why?
|
| Troponin I | 1 | 2013 | 25 | 0.020 |
Why?
|
| DNA Damage | 1 | 2013 | 97 | 0.020 |
Why?
|
| Affective Symptoms | 1 | 2013 | 17 | 0.020 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2013 | 89 | 0.020 |
Why?
|
| Secondary Prevention | 1 | 2013 | 74 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2013 | 157 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2014 | 803 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2014 | 781 | 0.020 |
Why?
|
| Nursing Assessment | 1 | 2011 | 12 | 0.020 |
Why?
|
| Mice | 1 | 2018 | 2720 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2017 | 2367 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2013 | 804 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 703 | 0.020 |
Why?
|
| Motor Activity | 1 | 2013 | 356 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2011 | 323 | 0.020 |
Why?
|
| Disability Evaluation | 1 | 2011 | 262 | 0.020 |
Why?
|
| Age Factors | 1 | 2013 | 1262 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2014 | 988 | 0.020 |
Why?
|
| Prognosis | 1 | 2013 | 1606 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2009 | 926 | 0.020 |
Why?
|
| Quality of Life | 1 | 2013 | 1032 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2011 | 1910 | 0.020 |
Why?
|
| North Carolina | 1 | 2011 | 1613 | 0.020 |
Why?
|
| Animals | 1 | 2018 | 8579 | 0.010 |
Why?
|